Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).

@article{Zeymer2013PredictorsCA,
  title={Predictors, cost, and outcomes of patients with acute coronary syndrome who receive optimal secondary prevention therapy: results from the antiplatelet treatment observational registries (APTOR).},
  author={Uwe Zeymer and Guy Berkenboom and Zdeněk Coufal and Mark A Belger and Magali Sartral and Kirsi Norrbacka and Ameet Bakhai},
  journal={International journal of cardiology},
  year={2013},
  volume={170 2},
  pages={239-45}
}
BACKGROUND We sought to evaluate outcomes, costs of care, quality of life and predictors at 12 months in patients with an acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) and evaluated use of optimal secondary prevention therapy, defined as use of aspirin and clopidogrel along with ≥ 3 of the following 4 therapies at both hospital discharge and at one-year post-PCI: statins, beta-blockers, ARB/ACE-inhibitors, and exercise or diet. METHODS Data were from the… CONTINUE READING

Citations

Publications citing this paper.

Similar Papers

Loading similar papers…